The therapeutic potential of sialylated Fc domains of human IgG

References

• Schauer R, Kamerling JP. Exploration of the Sialic Acid world. Adv Carbohydr Chem Biochem. 2018;75:1–12.
   PubMed Web of Science ®Google Scholar
• Dalziel M, Crispin M, Scanlan CN, Zitzmann N, Dwek RA. Emerging principles for the therapeutic exploitation of glycosylation. Science. 2014;343(6166):1235681–87. doi:10.1126/science.1235681.
   PubMed Web of Science ®Google Scholar
• Varki A, Gagneux P. Multifarious roles of sialic acids in immunity. Ann N Y Acad Sci. 2012;1253(1):16–36. doi:10.1111/j.1749-6632.2012.06517.x.
   PubMedGoogle Scholar
• Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science. 2001;293(5532):1155–59. doi:10.1126/science.1061692.
   PubMed Web of Science ®Google Scholar
• Mimura Y, Katoh T, Saldova R, O’Flaherty R, Izumi T, Mimura-Kimura Y, Utsunomiya T, Mizukami Y, Yamamoto K, Matsumoto T. Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy. Protein Cell. 2018;9(1):47–62. doi:10.1007/s13238-017-0433-3.
   PubMed Web of Science ®Google Scholar
• van de Bovenkamp FS, Hafkenscheid L, Rispens T, Rombouts Y. The emerging importance of IgG Fab glycosylation in immunity. J Immunol. 2016;196(4):1435–41. doi:10.4049/jimmunol.1502136.
   PubMed Web of Science ®Google Scholar
• Lund J, Takahashi N, Pound JD, Goodall M, Jefferis R. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fcy receptor I and influence the synthesis of its oligosaccharide chains. J Immunol. 1996;157:4963–69.
   PubMed Web of Science ®Google Scholar
• Wright A, Morrison SL. Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J Exp Med. 1994;180(3):1087–96. doi:10.1084/jem.180.3.1087.
   PubMed Web of Science ®Google Scholar
• Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R, Fiebiger B-M, Ravetch JV. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat Immunol. 2014;15(8):707–16. doi:10.1038/ni.2939.
   PubMed Web of Science ®Google Scholar
• Subedi GP, Hanson QM, Barb AW. Restricted motion of the Conserved Immunoglobulin G1 N-glycan is essential for efficient FcγRIIIa binding. Structure. 2014;22(10):1478–88. doi:10.1016/j.str.2014.08.002.
   PubMed Web of Science ®Google Scholar
• Shields RL, Lai J, Keck R, O’Connell LY, Hong K, Meng YG, Weikert SHA, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277(30):26733–40. doi:10.1074/jbc.M202069200.
   PubMed Web of Science ®Google Scholar
• Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278(5):3466–73. doi:10.1074/jbc.M210665200.
   PubMed Web of Science ®Google Scholar
• Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology. 2007;17(1):104–18. doi:10.1093/glycob/cwl057.
   PubMed Web of Science ®Google Scholar
• Yu M, Brown D, Reed C, Chung S, Lutman J, Stefanich E, Wong A, Stephan JP, Bayer R. Production, characterization and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans. MAbs. 2012;4(4):475–87. doi:10.4161/mabs.20737.
   PubMed Web of Science ®Google Scholar
• Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, Flynn GC. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology. 2011;21(7):949–59. doi:10.1093/glycob/cwr027.
   PubMed Web of Science ®Google Scholar
• Debre M, Bonnet MC, Fridman WH, Carosella E, Philippe N, Reinert P, Vilmer E, Kaplan C, Teillaud JL, Griscelli C. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet. 1993;342(8877):945–49. doi:10.1016/0140-6736(93)92000-J.
   PubMed Web of Science ®Google Scholar
• Liu L. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. J Pharm Sci. 2015;104(6):1866–84. doi:10.1002/jps.24444.
   PubMed Web of Science ®Google Scholar
• Zhang G, Massaad CA, Gao T, Pillai L, Bogdanova N, Ghauri S, Sheikh KA. Sialylated intravenous immunoglobulin suppress anti-ganglioside antibody mediated nerve injury. Exp Neurol. 2016;282:49–55. doi:10.1016/j.expneurol.2016.05.020.
   PubMed Web of Science ®Google Scholar
• Washburn N, Schwab I, Ortiz D, Bhatnagar N, Lansing JC, Medeiros A, Tyler S, Mekala D, Cochran E, Sarvaiya H. Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. Proc Natl Acad Sci U S A. 2015;112(11):E1297–306. doi:10.1073/pnas.1422481112.
   PubMed Web of Science ®Google Scholar
• Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science. 2008;320(5874):373–76. doi:10.1126/science.1154315.
   PubMed Web of Science ®Google Scholar
• Quast I, Keller CW, Maurer MA, Giddens JP, Tackenberg B, Wang L-X, Münz C, Nimmerjahn F, Dalakas MC, Lünemann JD. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. J Clin Invest. 2015;125(11):4160–70. doi:10.1172/JCI82695.
   PubMed Web of Science ®Google Scholar
• Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem. 1982;51(1):531–54. doi:10.1146/annurev.bi.51.070182.002531.
   PubMedGoogle Scholar
• Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, Buckley R, Chinen J, El-Gamal Y, Bd M. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the primary immunodeficiency committee of the American academy of allergy, asthma and Immunology. J Allergy Clin Immunol. 2006;117:525–53.
   PubMed Web of Science ®Google Scholar
• Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol. 2011;127(2):315–23. doi:10.1016/j.jaci.2010.10.030.
   PubMed Web of Science ®Google Scholar
• Stephen-Victor E, Bayry J. Multimerized IgG1 Fc molecule as an anti-inflammatory agent. Nat Rev Rheumatol. 2018;14(7):390–92. doi:10.1038/s41584-018-0013-9.
   PubMed Web of Science ®Google Scholar
• Lünemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology--mode of action and clinical efficacy. Nat Rev Neurol. 2015;11(2):80–89. doi:10.1038/nrneurol.2014.253.
   PubMed Web of Science ®Google Scholar
• Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system?. Nat Rev Immunol. 2013;13(3):176–89. doi:10.1038/nri3401.
   PubMed Web of Science ®Google Scholar
• Shock A, Humphreys D, Nimmerjahn F. Dissecting the mechanism of action of intravenous immunoglobulin in human autoimmune disease: lessons from therapeutic modalities targeting Fcγ receptors. J Allergy Clin Immunol. 2020;146(3):492–500. doi:10.1016/j.jaci.2020.06.036.
   PubMed Web of Science ®Google Scholar
• Li D, Lou Y, Zhang Y, Liu S, Li J, Tao J. Sialylated immunoglobulin G: a promising diagnostic and therapeutic strategy for autoimmune diseases. Theranostics. 2021;11(11):5430–46. doi:10.7150/thno.53961.
   PubMed Web of Science ®Google Scholar
• Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, Rademacher TW, Mizuochi T, Taniguchi T, Matsuta K. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature. 1985;316(6027):452–57. doi:10.1038/316452a0.
   PubMed Web of Science ®Google Scholar
• Scherer HU, Van Der Woude D, Ioan-Facsinay A, El Bannoudi H, Trouw LA, Wang J, Häupl T, Burmester GR, Deelder AM, Huizinga TWJ. Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum. 2010;62(6):1620–29. doi:10.1002/art.27414.
   PubMed Web of Science ®Google Scholar
• Van De Geijn FE, Wuhrer M, Selman MHJ, Willemsen SP, De Man YA, Deelder AM, Hazes JMW, Dolhain RJEM. Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. Arthritis Res Ther. 2009;11(6):1–10. doi:10.1186/ar2892.
   Web of Science ®Google Scholar
• Espy C, Morelle W, Kavian N, Grange P, Goulvestre C, Viallon V, Chéreau C, Pagnoux C, Michalski JC, Guillevin L. Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (wegener’s). Arthritis Rheum. 2011;63(7):2105–15. doi:10.1002/art.30362.
   PubMedGoogle Scholar
• Fokkink W-JR, Selman MHJ, Dortland JR, Durmuş B, Kuitwaard K, Huizinga R, van Rijs W, Tio-Gillen AP, Van Doorn PA, Deelder AM. IgG Fc N-Glycosylation in guillain–barré syndrome treated with immunoglobulins. J Proteome Res. 2014;13(3):1722–30. doi:10.1021/pr401213z.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006;313(5787):670–73. doi:10.1126/science.1129594.
   PubMed Web of Science ®Google Scholar
• Schwab I, Biburger M, Krönke G, Schett G, Nimmerjahn F. IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1. Eur J Immunol. 2012;42:826–30.
   PubMed Web of Science ®Google Scholar
• Schwab I, Mihai S, Seeling M, Kasperkiewicz M, Ludwig RJ, Nimmerjahn F. Broad requirement for terminal sialic acid residues and FcγRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo. Eur J Immunol. 2014;44(5):1444–53. doi:10.1002/eji.201344230.
   PubMed Web of Science ®Google Scholar
• Arroyo S, Tiessen RG, Denney WS, Jin J, Van Iersel MP (Thijs), Zeitz H, Am M, Mr S, JB B. Hyper-Sialylated IgG M254, an innovative therapeutic candidate, evaluated in healthy volunteers and in patients with immune thrombocytopenia purpura: safety, tolerability, pharmacokinetics, and pharmacodynamics. Blood. 2019;134(Supplement_1):1090. doi:10.1182/blood-2019-125993.
   Google Scholar
• Dekkers G, Plomp R, Koeleman CAM, Visser R, von Horsten HH, Sandig V, Rispens T, Wuhrer M, Vidarsson G. Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans. Sci Rep. 2016;6(1):36964. doi:10.1038/srep36964.
   PubMedGoogle Scholar
• Yu X, Baruah K, Harvey DJ, Vasiljevic S, Alonzi DS, Song BD, Higgins MK, Bowden TA, Scanlan CN, Crispin M. Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies. J Am Chem Soc. 2013;135(26):9723–32. doi:10.1021/ja4014375.
   PubMed Web of Science ®Google Scholar
• Cymer F, Beck H, Rohde A, Reusch D. Therapeutic monoclonal antibody N-glycosylation - structure, function and therapeutic potential. Biologicals. 2018;52:1–11. doi:10.1016/j.biologicals.2017.11.001.
   PubMed Web of Science ®Google Scholar
• Makita S, Tobinai K. Mogamulizumab for the treatment of T-cell lymphoma. Expert Opin Biol Ther. 2017;17(9):1145–53. doi:10.1080/14712598.2017.1347634.
   PubMed Web of Science ®Google Scholar
• Huang W, Giddens J, Fan SQ, Toonstra C, Wang LX. Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions. J Am Chem Soc. 2012;134(29):12308–18. doi:10.1021/ja3051266.
   PubMed Web of Science ®Google Scholar
• Yu X, Vasiljevic S, Mitchell DA, Crispin M, Scanlan CN. Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain. J Mol Biol. 2013;425(8):1253–58. doi:10.1016/j.jmb.2013.02.006.
   PubMed Web of Science ®Google Scholar
• Mahajan VS, Pillai S. Sialic acids and autoimmune disease. Immunol Rev. 2016;269(1):145–61. doi:10.1111/imr.12344.
   PubMed Web of Science ®Google Scholar
• Lübbers J, Rodríguez E, Van Kooyk Y. Modulation of immune tolerance via siglec-Sialic Acid interactions. Front Immunol. 2018;9:2807. doi:10.3389/fimmu.2018.02807.
   PubMed Web of Science ®Google Scholar
• Czajkowsky DM, Andersen JT, Fuchs A, Wilson TJ, Mekhaiel D, Colonna M, He J, Shao Z, Mitchell DA, Wu G. Developing the IVIG biomimetic, Hexa-Fc, for drug and vaccine applications. Sci Rep. 2015;5(1):9526. doi:10.1038/srep09526.
   PubMedGoogle Scholar
• Crispin M, Yu X, Bowden TA. Crystal structure of sialylated IgG Fc: implications for the mechanism of intravenous immunoglobulin therapy. Proc Natl Acad Sci. 2013;110(38):3544–46. doi:10.1073/pnas.1310657110.
   Web of Science ®Google Scholar
• Tang F, Wang L-X HW. Chemoenzymatic synthesis of glycoengineered IgG antibodies and glycosite-specific antibody–drug conjugates. Nat Protoc. 2017;12(8):1702–21. doi:10.1038/nprot.2017.058.
   PubMed Web of Science ®Google Scholar
• Blundell PA, Le NPL, Allen J, Watanabe Y, Pleass RJ. Engineering the fragment crystallizable (Fc) region of human IgG1 multimers and monomers to fine-tune interactions with sialic acid-dependent receptors. J Biol Chem. 2017;292(31):12994–3007. doi:10.1074/jbc.M117.795047.
   PubMed Web of Science ®Google Scholar
• Blundell PA, Lu D, Dell A, Haslam S, Pleass RJ. Choice of host cell line is essential for the functional glycosylation of the Fc Region of human IgG1 inhibitors of influenza B viruses. J Immunol. 2020;204(4):1022–34. doi:10.4049/jimmunol.1901145.
   PubMed Web of Science ®Google Scholar
• Blundell PA, Lu D, Wilkinson M, Dell A, Haslam S, Pleass RJ. Insertion of N-terminal hinge glycosylation enhances interactions of the Fc Region of human IgG1 monomers with glycan-dependent receptors and blocks hemagglutination by the influenza virus. J Immunol. 2019;202:1595–611.
   PubMed Web of Science ®Google Scholar
• Mekhaiel DNA, Czajkowsky DM, Andersen JT, Shi J, El-Faham M, Doenhoff M, McIntosh RS, Sandlie I, He J, Hu J. Polymeric human Fc-fusion proteins with modified effector functions. Sci Rep. 2011;1:124. 10.1038/srep00124
   Web of Science ®Google Scholar
• Böhm M, Bohne-Lang A, Frank M, Loss A, Rojas-Macias MA, Lütteke T. Glycosciences.DB: an annotated data collection linking glycomics and proteomics data (2018 update). Nucleic Acids Res. 2019;47(D1):D1195–201. doi:10.1093/nar/gky994.
   PubMed Web of Science ®Google Scholar
• Baksmeier C, Blundell P, Steckel J, Schultz V, Gu Q, Da Silva Filipe A, Kohl A, Linnington C, Lu D, Dell A. Modified recombinant human IgG1-Fc is superior to natural IVIG at inhibiting immune-mediated demyelination. Immunology. 2021;00:1–16.
   Google Scholar
• Tradtrantip L, Felix CM, Spirig R, Morelli AB, Verkman AS. Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in vitro and rat models of neuromyelitis optica. Neuropharmacology. 2018;133:345–53. doi:10.1016/j.neuropharm.2018.02.002.
   PubMed Web of Science ®Google Scholar
• Spirig R, Campbell IK, Koernig S, Chen C-G, Lewis BJB, Butcher R, Muir I, Taylor S, Chia J, Leong D. rIgG1 Fc hexamer inhibits antibody-mediated autoimmune disease via effects on complement and FcγRs. J Immunol. 2018;200(8):2542–53. doi:10.4049/jimmunol.1701171.
   PubMed Web of Science ®Google Scholar
• Zuercher AW, Spirig R, Baz Morelli A, Rowe T, Käsermann F. Next-generation Fc receptor–targeting biologics for autoimmune diseases. Autoimmun Rev. 2019;18(10):102366. doi:10.1016/j.autrev.2019.102366.
   PubMed Web of Science ®Google Scholar
• Karsten CM, Pandey MK, Figge J, Kilchenstein R, Taylor PR, Rosas M, McDonald JU, Orr SJ, Berger M, Petzold D. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB and dectin-1. Nat Med. 2012;18(9):1401–06. doi:10.1038/nm.2862.
   PubMed Web of Science ®Google Scholar
• Lux A, Yu X, Scanlan CN, Nimmerjahn F. Impact of immune complex size and glycosylation on IgG binding to human FcγRs. J Immunol. 2013;190(8):4315–23. doi:10.4049/jimmunol.1200501.
   PubMed Web of Science ®Google Scholar
• Campbell IK, Miescher S, Branch DR, Mott PJ, Lazarus AH, Han D, Maraskovsky E, Zuercher AW, Neschadim A, Leontyev D. Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils. J Immunol. 2014;192(11):5031–38. doi:10.4049/jimmunol.1301611.
   PubMed Web of Science ®Google Scholar
• JM F, Kr A, Rp B, Ha H, EE W, Wa B. Antibody blood-brain barrier efflux is modulated by glycan modification. Biochim Biophys Acta - Gen Subj. 2017;1861(9):2228–39. doi:10.1016/j.bbagen.2017.06.008.
   PubMed Web of Science ®Google Scholar
• Zhang G, Massaad CA, Gao T, Pillai L, Bogdanova N, Ghauri S, Sheikh KA. Sialylated intravenous immunoglobulin suppress anti-ganglioside antibody mediated nerve injury. Exp Neurol. 2016;282:49–55. doi:10.1017/j.expneurol.2016.05.020.
   PubMed Web of Science ®Google Scholar
• MacAuley MS, Crocker PR, Paulson JC. Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol. 2014;14(10):653–66. doi:10.1038/nri3737.
   PubMed Web of Science ®Google Scholar
• Movsisyan LD, Macauley MS. Structural advances of siglecs: insight into synthetic glycan ligands for immunomodulation. Org Biomol Chem. 2020;18(30):5784–97. doi:10.1039/D0OB01116A.
   PubMed Web of Science ®Google Scholar
• Crocker PR, Redelinghuys P. Siglecs as positive and negative regulators of the immune system. Biochem Soc Trans. 2008;36(6):1467–71. doi:10.1042/BST0361467.
   PubMedGoogle Scholar
• Delaveris CS, Chiu SH, Riley NM, Bertozzi CR. Modulation of immune cell reactivity with cis-binding siglec agonists. Proc Natl Acad Sci U S A. 2021;118(3):e2012408118. doi: 10.1073/pnas.2012408118
   Web of Science ®Google Scholar
• Bondioli L, Ruozi B, Belletti D, Forni F, Vandelli MA, Tosi G. Sialic acid as a potential approach for the protection and targeting of nanocarriers. Expert Opin Drug Deliv. 2011;8(7):921–37. doi:10.1517/17425247.2011.577061.
   PubMed Web of Science ®Google Scholar
• Courtney AH, Puffer EB, Pontrello JK, Yang ZQ, Kiessling LL. Sialylated multivalent antigens engage CD22 in trans and inhibit B cell activation. Proc Natl Acad Sci U S A. 2009;(8). doi:10.1073/pnas.0807207106.
   Web of Science ®Google Scholar
• Rillahan CD, Schwartz E, McBride R, Fokin VV, Paulson JC. Click and pick: identification of sialoside analogues for siglec-based cell targeting. Angew Chemie. 2012;51(44):11014–18. doi:10.1002/anie.201205831.
   PubMed Web of Science ®Google Scholar
• Flynn RA, Pedram K, Malaker SA, Batista PJ, Smith BAH, Johnson AG, George BM, Majzoub K, Villalta PW, Carette JE. Small RNAs are modified with N-glycans and displayed on the surface of living cells. Cell. 2021;(12). doi:10.1016/j.cell.2021.04.023.
   Web of Science ®Google Scholar
• Spence S, Greene MK, Fay F, Hams E, Saunders SP, Hamid U, Fitzgerald M, Beck J, Bains BK, Smyth P. Targeting siglecs with a sialic acid-decorated nanoparticle abrogates inflammation. Sci Transl Med. 2015;7(303):1–13. doi:10.1126/scitranslmed.aab3459.
   Web of Science ®Google Scholar
• Kilcoyne M, Joshi L. Translational Glycobiology in Human Health and Disease. Academic Press,London; 2020. ISBN 9780128196557.
   Google Scholar
• Miles LA, Hermans SJ, Crespi GAN, Gooi JH, Doughty L, Nero TL, Markulić J, Ebneth A, Wroblowski B, Oehlrich D. Small molecule binding to alzheimer risk factor CD33 promotes Aβ phagocytosis. iScience. 2019;19:110–18. doi:10.1016/j.isci.2019.07.023.
   PubMed Web of Science ®Google Scholar
• Lajaunias F, Dayer JM, Chizzolini C. Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling. Eur J Immunol. 2005;35(1):243–51. doi:10.1002/eji.200425273.
   PubMed Web of Science ®Google Scholar
• Waldmann M, Jirmann R, Hoelscher K, Wienke M, Niemeyer FC, Rehders D, Meyer B. A nanomolar multivalent ligand as entry inhibitor of the hemagglutinin of avian influenza. J Am Chem Soc. 2014;136(2):783–88. doi:10.1021/ja410918a.
   PubMed Web of Science ®Google Scholar
• Cartellieri M, Feldmann A, Koristka S, Arndt C, Loff S, Ehninger A, von Bonin M, Bejestani EP, Ehninger G, Bachmann MP. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. Blood Cancer J. 2016;6(8):e458. doi:10.1038/bcj.2016.61.
   PubMed Web of Science ®Google Scholar
• Estus S, Bc S, Devanney N, Katsumata Y, EE P, DW F. Evaluation of CD33 as a genetic risk factor for alzheimer’s disease. Acta Neuropathol. 2019;138:187–99.
   PubMed Web of Science ®Google Scholar
• Murch SH. Common determinants of severe covid-19 infection are explicable by SARS-CoV-2 secreted glycoprotein interaction with the CD33-related siglecs, siglec-3 and siglec-5/14. Med Hypotheses. 2020;144:110168. doi:10.1016/j.mehy.2020.110168.
   PubMed Web of Science ®Google Scholar
• Rodrigues E, Jung J, Park H, Loo C, Soukhtehzari S, Kitova EN, Mozaneh F, Daskhan G, Schmidt EN, Aghanya V. A versatile soluble siglec scaffold for sensitive and quantitative detection of glycan ligands. Nat Commun. 2020;11(1):5091. doi:10.1038/s41467-020-18907-6.
   PubMed Web of Science ®Google Scholar
• Blundell P, Pleass R. A method to detect the binding of hyper-glycosylated fragment crystallizable (Fc) region of human IgG1 to glycan receptors. Methods Mol Biol. 2019;1904:417–21.
   PubMedGoogle Scholar
• Matrosovich M, Herrler G, Klenk HD. Sialic acid receptors of viruses. SialoGlyco Chem Biol II. 2015;367:1–28.
   Google Scholar
• Stencel-Baerenwald JE, Reiss K, Reiter DM, Stehle T, Dermody TS. The sweet spot: defining virus-sialic acid interactions. Nat Rev Microbiol. 2014;12(11):739–49. doi:10.1038/nrmicro3346.
   PubMed Web of Science ®Google Scholar
• Vahey MD, Fletcher DA. Influenza A virus surface proteins are organized to help penetrate host mucus. Elife. 2019;8:e43764. doi:10.7554/eLife.43764.
   PubMed Web of Science ®Google Scholar
• Jj S, Dc W. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem. 2000;69(1):531–69. doi:10.1146/annurev.biochem.69.1.531.
   PubMedGoogle Scholar
• Bandlow V, Lauster D, Ludwig K, Hilsch M, Reiter-Scherer V, Rabe JP, Böttcher C, Herrmann A, Seitz O. Sialyl-LacNAc-PNA⋅DNA concatamers by rolling-circle amplification as multivalent inhibitors of influenza A virus particles. ChemBioChem. 2019;20:1–8.
   Web of Science ®Google Scholar
• Bandlow V, Liese S, Lauster D, Ludwig K, Netz RR, Herrmann A, Seitz O. Spatial screening of hemagglutinin on influenza A virus particles: sialyl-LacNAc displays on DNA and PEG scaffolds reveal the requirements for bivalency enhanced interactions with weak monovalent binders. J Am Chem Soc. 2017;139(45):16389–97. doi:10.1021/jacs.7b09967.
   PubMed Web of Science ®Google Scholar
• Tang S, Puryear WB, Seifried BM, Dong X, Runstadler JA, Ribbeck K, Olsen BD. Antiviral agents from multivalent presentation of sialyl oligosaccharides on brush polymers. ACS Macro Lett. 2016;5(3):413–18. doi:10.1021/acsmacrolett.5b00917.
   PubMed Web of Science ®Google Scholar
• Kwon S-J, Na DH, Kwak JH, Douaisi M, Zhang F, Park EJ, Park J-H, Youn H, Song C-S, Kane RS. Nanostructured glycan architecture is important in the inhibition of influenza A virus infection. Nat Nanotechnol. 2017;12(1):48–54. doi:10.1038/nnano.2016.181.
   PubMed Web of Science ®Google Scholar
• Papp I, Sieben C, Sisson AL, Kostka J, Böttcher C, Ludwig K, Herrmann A, Haag R. Inhibition of influenza virus activity by multivalent glycoarchitectures with matched sizes. ChemBioChem. 2011;12(6):887–95. doi:10.1002/cbic.201000776.
   PubMed Web of Science ®Google Scholar
• Sigal GB, Mammen M, Dahmann G, Whitesides GM. Polyacrylamides bearing pendant α-sialoside groups strongly inhibit agglutination of erythrocytes by influenza virus: the strong inhibition reflects enhanced binding through cooperative polyvalent interactions. J Am Chem Soc. 1996;118(16):3789–800. doi:10.1021/ja953729u.
   Web of Science ®Google Scholar
• Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol. 2005;23(11):1418–23. doi:10.1038/nbt1159.
   PubMed Web of Science ®Google Scholar
• Delaveris CS, Webster ER, Banik SM, Boxer SG, Bertozzi CR. Membrane-tethered mucin-like polypeptides sterically inhibit binding and slow fusion kinetics of influenza A virus. Proc Natl Acad Sci U S A. 2020;117(23):12643–50. doi:10.1073/pnas.1921962117.
   PubMed Web of Science ®Google Scholar
• Ghosh S. Nanotechnology and sialic acid biology. Academic Press, London; 2020. ISBN 9780128161265.
   Google Scholar
• Nel A, Xia T, Mädler L, Li N. Toxic potential of materials at the nanolevel. Science. 2006;311(5761):622–27. doi:10.1126/science.1114397.
   PubMed Web of Science ®Google Scholar
• Rathor S, Bhatt DC, Aamir S, Singh SK, Kumar V. A comprehensive review on role of nanoparticles in therapeutic delivery of medicine. Pharm Nanotechnol. 2017;5:263–75.
   PubMedGoogle Scholar
• Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE, Wilson IA. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science. 2010;328(5976):357–60. doi:10.1126/science.1186430.
   PubMed Web of Science ®Google Scholar
• Wang Q, Cheng F, Lu M, Tian X, Ma J. Crystal structure of unliganded influenza B virus hemagglutinin. J Virol. 2008;82(6):3011–20. doi:10.1128/JVI.02477-07.
   PubMed Web of Science ®Google Scholar
• Ahmed AA, Giddens J, Pincetic A, Lomino JV, Ravetch JV, Wang LX, Bjorkman PJ. Structural characterization of anti-inflammatory immunoglobulin G Fc proteins. J Mol Biol. 2014;426(18):3166–79. doi:10.1016/j.jmb.2014.07.006.
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol. 2016;13(1):3–10. doi:10.1038/cmi.2015.74.
   PubMed Web of Science ®Google Scholar
• Maurer MA, Meyer L, Bianchi M, Turner HL, Le NPL, Steck M, Wyrzucki A, Orlowski V, Ward AB, Crispin M. Glycosylation of human IgA directly inhibits influenza A and other Sialic-Acid-binding viruses. Cell Rep. 2018;23(1):90–99. doi:10.1016/j.celrep.2018.03.027.
   PubMed Web of Science ®Google Scholar
• Sandin S, Öfverstedt LG, Wikström AC, Ö W, Skoglund U. Structure and flexibility of individual immunoglobulin G molecules in solution. Structure. 2004;12(3):409–15. doi:10.1016/j.str.2004.02.011.
   PubMed Web of Science ®Google Scholar
• Weis W, Jh B, Cusack S, JC P, Jj S, Dc W. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature. 1988;333(6172):426–31. doi:10.1038/333426a0.
   PubMed Web of Science ®Google Scholar
• Hong M, Lee PS, Hoffman RMB, Zhu X, Krause JC, Laursen NS, Yoon S-I, Song L, Tussey L, JE C. Antibody recognition of the pandemic H1N1 influenza virus hemagglutinin receptor binding site. J Virol. 2013;87(22):12471–80. doi:10.1128/JVI.01388-13.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Nei M. Origin and evolution of influenza virus hemagglutinin genes. Mol Biol Evol. 2002;19(4):501–09. doi:10.1093/oxfordjournals.molbev.a004105.
   PubMed Web of Science ®Google Scholar
• Ernst B, Magnani JL. From carbohydrate leads to glycomimetic drugs. Nat Rev Drug Discov. 2009;8(8):661–77. doi:10.1038/nrd2852.
   PubMed Web of Science ®Google Scholar
• Gao Z, Niikura M, Withers SG. Ultrasensitive fluorogenic reagents for neuraminidase titration. Angew Chemie - Int Ed. 2017;56(22):6112–16. doi:10.1002/anie.201610544.
   PubMed Web of Science ®Google Scholar
• Roy MG, Livraghi-Butrico A, Fletcher AA, McElwee MM, Evans SE, Boerner RM, Alexander SN, Bellinghausen LK, Song AS, Petrova YM. Muc5b is required for airway defence. Nature. 2014;505(7483):412–16. doi:10.1038/nature12807.
   PubMed Web of Science ®Google Scholar
• Zanin M, Baviskar P, Webster R, Webby R. The interaction between respiratory pathogens and mucus. Cell Host Microbe. 2016;19(2):159–68. doi:10.1016/j.chom.2016.01.001.
   PubMed Web of Science ®Google Scholar
• Bansil R, Turner BS. The biology of mucus: composition, synthesis and organization. Adv Drug Deliv Rev. 2018;124:3–15. doi:10.1016/j.addr.2017.09.023.
   PubMed Web of Science ®Google Scholar
• Alejandra Tortorici M, Walls AC, Lang Y, Wang C, Li Z, Koerhuis D, Boons GJ, Bosch BJ, Rey FA, de Groot RJ. Structural basis for human coronavirus attachment to sialic acid receptors. Nat Struct Mol Biol. 2019;26(6):481–89. doi:10.1038/s41594-019-0233-y.
   PubMed Web of Science ®Google Scholar
• Chambers BS, Li Y, Hodinka RL, Hensley SE. Recent H3N2 influenza virus clinical isolates rapidly acquire hemagglutinin or neuraminidase mutations when propagated for antigenic analyses. J Virol. 2014;88(18):10986–89. doi:10.1128/JVI.01077-14.
   PubMed Web of Science ®Google Scholar
• Peng W, De Vries RP, Grant OC, Thompson AJ, McBride R, Tsogtbaatar B, Lee PS, Razi N, Wilson IA, Woods RJ. Recent H3N2 viruses have evolved specificity for extended, branched human-type receptors, conferring potential for increased avidity. Cell Host Microbe. 2017;21(1):23–34. doi:10.1016/j.chom.2016.11.004.
   PubMed Web of Science ®Google Scholar
• Broszeit F, van Beek RJ, Unione L, Bestebroer TM, Chapla D, Yang JY, Moremen KW, Herfst S, Fouchier RAM, De Vries RP. Glycan remodeled erythrocytes facilitate antigenic characterization of recent A/H3N2 influenza viruses. bioRxiv. 2020. doi.10.1101/2020.12.18.423398
   Google Scholar
• Trichonas G, Kaiser PK. Aflibercept for the treatment of age-related macular degeneration. Ophthalmol Ther. 2013;2(2):89–98. doi:10.1007/s40123-013-0015-2.
   PubMedGoogle Scholar
• Faghihi H, Najafabadi AR, Daman Z, Ghasemian E, Montazeri H, Vatanara A. Respiratory administration of infliximab dry powder for local suppression of inflammation. AAPS PharmSciTech. 2019;20(3):128. doi:10.1208/s12249-019-1308-0.
   PubMed Web of Science ®Google Scholar